A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Expert Opin Drug Saf. 2013 Sep;12(5):793-4.
doi: 10.1517/14740338.2013.829452.
Epub 2013 Aug 12.